NO952295L - Spiropiperidiner og homologer som aktiverer frigivelse av veksthormon - Google Patents

Spiropiperidiner og homologer som aktiverer frigivelse av veksthormon

Info

Publication number
NO952295L
NO952295L NO952295A NO952295A NO952295L NO 952295 L NO952295 L NO 952295L NO 952295 A NO952295 A NO 952295A NO 952295 A NO952295 A NO 952295A NO 952295 L NO952295 L NO 952295L
Authority
NO
Norway
Prior art keywords
growth hormone
homologs
spiropiperidines
humans
promote
Prior art date
Application number
NO952295A
Other languages
English (en)
Norwegian (no)
Other versions
NO952295D0 (no
Inventor
Meng-Hsin Chen
David B R Johnston
Ravi P Nargund
Arthur A Patchett
James R Tata
Lihu Yang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/147,226 external-priority patent/US5536716A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO952295D0 publication Critical patent/NO952295D0/no
Publication of NO952295L publication Critical patent/NO952295L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO952295A 1992-12-11 1995-06-09 Spiropiperidiner og homologer som aktiverer frigivelse av veksthormon NO952295L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98932292A 1992-12-11 1992-12-11
US08/147,226 US5536716A (en) 1992-12-11 1993-11-03 Spiro piperidines and homologs which promote release of growth hormone
PCT/US1993/011038 WO1994013696A1 (en) 1992-12-11 1993-11-15 Spiro piperidines and homologs which promote release of growth hormone

Publications (2)

Publication Number Publication Date
NO952295D0 NO952295D0 (no) 1995-06-09
NO952295L true NO952295L (no) 1995-08-10

Family

ID=26844709

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952295A NO952295L (no) 1992-12-11 1995-06-09 Spiropiperidiner og homologer som aktiverer frigivelse av veksthormon

Country Status (27)

Country Link
US (1) US5652235A (hr)
EP (1) EP0615977B1 (hr)
JP (1) JP2509530B2 (hr)
CN (1) CN1034733C (hr)
AT (1) ATE220071T1 (hr)
AU (1) AU673552B2 (hr)
BG (1) BG61979B1 (hr)
CA (1) CA2110670C (hr)
CZ (1) CZ151495A3 (hr)
DE (1) DE69332075T2 (hr)
DK (1) DK0615977T3 (hr)
DZ (1) DZ1736A1 (hr)
ES (1) ES2177538T3 (hr)
FI (1) FI952863A0 (hr)
HR (1) HRP931486B1 (hr)
HU (2) HUT72076A (hr)
IL (1) IL107837A0 (hr)
MX (1) MX9307850A (hr)
NO (1) NO952295L (hr)
NZ (1) NZ258412A (hr)
PL (1) PL176993B1 (hr)
PT (1) PT615977E (hr)
RO (1) RO115804B1 (hr)
RU (1) RU2168512C2 (hr)
SI (1) SI9300646A (hr)
SK (1) SK282166B6 (hr)
WO (1) WO1994013696A1 (hr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
BR9407869A (pt) * 1993-10-19 1996-10-29 Merck & Co Inc Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1995034311A1 (en) * 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
US5783582A (en) * 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
GB9415996D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5656606A (en) * 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996033189A1 (en) * 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (en) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
CA2235511A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
AU707946B2 (en) * 1995-10-27 1999-07-22 Merck Sharp & Dohme Corp. Polymorphic forms of a growth hormone secretagogue
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
ATE334394T1 (de) 1995-12-13 2006-08-15 Merck & Co Inc Testverfahren für die sekretionsrezeptoren von wachstumshormonen
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1997022367A1 (en) * 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
WO1997044042A1 (en) * 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
JP2001502319A (ja) * 1996-10-15 2001-02-20 藤沢薬品工業株式会社 成長ホルモンの放出を促進するベンズオキセピン誘導体
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
WO1998018815A1 (en) * 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JP2000514838A (ja) * 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
JP3514774B2 (ja) * 1997-06-25 2004-03-31 ファイザー・インク 成長ホルモン分泌促進薬としてのジペプチド誘導体
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
WO2000001726A1 (en) * 1998-06-30 2000-01-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
EP1112282A4 (en) 1998-08-10 2002-10-31 Merck & Co Inc RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AU2686899A (en) * 1998-08-18 2000-03-14 Eli Lilly And Company Growth hormone secretagogues
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
EP1158996A4 (en) * 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
JP2002523368A (ja) * 1999-02-19 2002-07-30 イーライ・リリー・アンド・カンパニー 成長ホルモン分泌促進薬
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6803372B2 (en) 1999-08-20 2004-10-12 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6462053B1 (en) 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2386517A1 (en) * 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
ATE302184T1 (de) 2000-02-18 2005-09-15 Meiji Seika Kaisha Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
US7157463B2 (en) 2001-01-23 2007-01-02 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
US7169777B2 (en) 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
AP1699A (en) * 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
WO2002094825A1 (fr) * 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
EP1469851B1 (en) 2002-01-23 2006-10-11 Eli Lilly And Company Melanocortin receptor agonists
ATE338767T1 (de) * 2002-04-09 2006-09-15 Lilly Co Eli Dipeptidische wachstumshormonsekretionsförderern
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
CA2487976C (en) 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
BRPI0408295A (pt) * 2003-03-14 2006-03-07 Merck Sharp & Dohme uso de um composto
CN1297557C (zh) * 2003-04-10 2007-01-31 上海药明康德新药开发有限公司 螺环类模板化合物的制备
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
GB0328906D0 (en) * 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
CN100345851C (zh) * 2004-01-02 2007-10-31 上海药明康德新药开发有限公司 螺二氢吲哚类模板化合物及其制备方法
US20050261332A1 (en) * 2004-04-02 2005-11-24 Distefano Peter Sulfonamides and uses thereof
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
RU2007109794A (ru) * 2004-08-19 2008-09-27 Вертекс Фармасьютикалз, Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
AU2005309365B2 (en) * 2004-11-29 2011-10-06 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1988892A2 (en) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ATE517106T1 (de) 2006-02-22 2011-08-15 Vertex Pharma Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101500565A (zh) 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
CN101553231A (zh) 2006-08-15 2009-10-07 弗特克斯药品有限公司 毒蕈碱受体调节剂
JP2010501561A (ja) * 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
WO2008056687A1 (fr) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
CA2700724A1 (en) * 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2010093578A1 (en) * 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
EP2275421A1 (en) * 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
JP5883863B2 (ja) * 2010-07-28 2016-03-15 ザ ユニバーシティ オブ クィーンズランド プロテアーゼ活性化受容体の調節剤
AR086554A1 (es) * 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
TW201607927A (zh) * 2014-08-28 2016-03-01 愛沃特股份有限公司 異喹啉類之製造方法
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
RU2020130837A (ru) 2018-02-21 2022-03-21 ЭйАй ТЕРАПЬЮТИКС, ИНК. Комбинационная терапия апилимодом и глутаматергическими агентами
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332704D0 (en) * 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone

Also Published As

Publication number Publication date
FI952863A (fi) 1995-06-09
HRP931486B1 (en) 2003-08-31
DE69332075T2 (de) 2003-01-16
AU5232093A (en) 1994-06-23
ATE220071T1 (de) 2002-07-15
JP2509530B2 (ja) 1996-06-19
SI9300646A (en) 1994-09-30
ES2177538T3 (es) 2002-12-16
CZ151495A3 (en) 1995-12-13
FI952863A0 (fi) 1995-06-09
JPH06263737A (ja) 1994-09-20
WO1994013696A1 (en) 1994-06-23
RU2168512C2 (ru) 2001-06-10
PL309331A1 (en) 1995-10-02
NZ258412A (en) 1997-01-29
CN1092071A (zh) 1994-09-14
BG99710A (bg) 1996-01-31
MX9307850A (es) 1994-06-30
HUT72076A (en) 1996-03-28
HU211301A9 (en) 1995-11-28
SK75995A3 (en) 1995-11-08
BG61979B1 (bg) 1998-11-30
PT615977E (pt) 2002-10-31
CN1034733C (zh) 1997-04-30
IL107837A0 (en) 1994-04-12
NO952295D0 (no) 1995-06-09
EP0615977A1 (en) 1994-09-21
SK282166B6 (sk) 2001-11-06
HRP931486A2 (hr) 1995-02-28
US5652235A (en) 1997-07-29
AU673552B2 (en) 1996-11-14
EP0615977B1 (en) 2002-07-03
DZ1736A1 (fr) 2002-02-17
DK0615977T3 (da) 2002-07-22
HU9501683D0 (en) 1995-08-28
RO115804B1 (ro) 2000-06-30
PL176993B1 (pl) 1999-08-31
CA2110670C (en) 2001-04-17
CA2110670A1 (en) 1994-06-12
DE69332075D1 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
NO952295L (no) Spiropiperidiner og homologer som aktiverer frigivelse av veksthormon
MY131439A (en) Spiro piperidines and homologs promote release of growth hormone
PH31168A (en) Spiro piperidines and homologs promote release of growth hormone.
IL101206A0 (en) Benzo-fused lactams,their preparation and pharmaceutical compositions containing them
DE69331197D1 (de) Die freisetzung von wachstumshormon stimulierende benzoverknüpfte lactame
DK1179984T3 (da) Metode til fremstilling af en sammensætning til forbedring af immunforsvaret hos kæledyr under anvendelse af en kombination af antioxidanter
GB0300396D0 (en) Dietary regime for companion animals
ATE266658T1 (de) Amido-spiropiperidine promovieren die freisetzung von wachstumshormonen
ITMI910705U1 (it) Manufatti per l'alimentazione stimolatori dell'assunzione del cibo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application